Company

Prelude Therapeutics Inc.

Prelude Therapeutics Inc. is a Wilmington-based precision oncology company developing SMARCA2 and KAT6A degraders for cancer.

About

Founded in 2016 and headquartered in Wilmington, US, Prelude Therapeutics is led by CEO Kris Vaddi. Its pipeline includes degrader molecules for ER+ breast cancer and other solid tumors, as well as CDK9 and CDK4/6 inhibitors. In December 2023 it raised USD 25 mn in a private placement, selling 7.9 million shares at USD 3.15 per share on the NASDAQ.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in